Beta BionicsBBNX +1.71%10 Quick Ratio is 9.67 as of Mar. 2026, which is 0% above its 10-year median of 9.65. GuruFocus rates BBNX with a GF Score™ of 10/100. The stock has 3 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Beta Bionics ranks better than 94.26% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Beta Bionics's quick ratio for the quarter that ended in Mar. 2026 was 9.67.
Beta Bionics has a quick ratio of 9.67. It generally indicates good short-term financial strength.
The historical rank and industry rank for Beta Bionics's Quick Ratio or its related term are showing as below:
BBNX'
s Quick Ratio Range Over the Past 10 Years
Min: 3.21 Med: 9.65 Max: 14.93
Current: 9.67
During the past 4 years, Beta Bionics's highest Quick Ratio was 14.93. The lowest was 3.21. And the median was 9.65.
BBNX's Quick Ratio is ranked better than 94.26% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 1.885
vs BBNX: 9.67
Beta Bionics (NAS:BBNX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Beta Bionics Quick Ratio Related Terms
Beta Bionics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Beta Bionics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Beta Bionics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beta Bionics Quick Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Beta Bionics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Beta Bionics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Beta Bionics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beta Bionics (BBNX) has a Quick Ratio of 9.67 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Beta Bionics and its competitors. This is near median its historical median of 9.65. Over the past decade, Beta Bionics' Quick Ratio has ranged from 3.21 to 14.93. According to the industry distribution chart, Beta Bionics ranks #49 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 5.7%.
Is Beta Bionics' Quick Ratio too high?
Beta Bionics' current Quick Ratio of 9.67 is near median its 10-year median of 9.65. Over the past 10 years, this metric has ranged from a low of 3.21 to a high of 14.93. The Medical Devices & Instruments industry median Quick Ratio is 1.89. Beta Bionics' value of 9.67 is 413% above this industry median. Based on the distribution chart, Beta Bionics ranks #49 out of 854 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Beta Bionics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Beta Bionics' Quick Ratio compare to CBLL and SIBN?
According to the Medical Devices & Instruments industry distribution chart, Beta Bionics ranks #49 out of 854 companies for Quick Ratio. This places Beta Bionics in the top 6% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.89. Beta Bionics' value of 9.67 is 413% above this benchmark. Historically, Beta Bionics' own Quick Ratio has ranged from 3.21 to 14.93 over the past decade. While the company's 10-year median is 9.65 vs. the industry median of 1.89, Beta Bionics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Devices & Instruments company?
The median Quick Ratio among Medical Devices & Instruments companies is 1.89, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beta Bionics's current Quick Ratio of 9.67 is 413% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Beta Bionics and its competitors. For the Medical Devices & Instruments industry, the median Quick Ratio is 1.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beta Bionics's current Quick Ratio is 9.67, which is near median its own 10-year median of 9.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Bionics stock overvalued right now?
Beta Bionics (BBNX) has a current Quick Ratio of 9.67. The current Quick Ratio is 9.67, which is near median its 10-year median of 9.65 and 413% above the Medical Devices & Instruments industry median of 1.89. Beta Bionics' overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Beta Bionics (BBNX), the current Quick Ratio is 9.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
10GF Score
Get the complete analysis for BBNX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBNX has been successfully added to your 
